3-(4,4-dimethylpiperidin-1-yl)propan-1-amine | 869493-55-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 英文名称: 3-(4,4-dimethylpiperidin-1-yl)propan-1-amine
• CAS: 869493-55-0
• 化学式: C₁₀H₂₂N₂
• 分子量: 170.298
• InChiKey: YVMACWYUJMRASZ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.4
• 重原子数：
  12
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  29.3
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  3-(4,4-dimethylpiperidin-1-yl)propan-1-amine 、 1-((5-methyl-2-(o-tolyl)oxazol-4-yl)methyl)piperidine-4-carboxylic acid 在 1-羟基苯并三唑一水物 、 N,N'-二异丙基碳二亚胺 作用下， 以 乙腈 为溶剂， 反应 0.17h， 以70%的产率得到N-(3-(4,4-dimethylpiperidin-1-yl)propyl)-1-((5-methyl-2-(o-tolyl)-oxazol-4-yl)methyl)piperidine-4-carboxamide.
  参考文献：
  名称：

  Development of an Aryloxazole Class of Hepatitis C Virus Inhibitors Targeting the Entry Stage of the Viral Replication Cycle

  摘要：

  Reliance on hepatitis C virus (HCV) replicon systems and protein-based screening assays has led to treatments that target HCV viral replication proteins. The model does not encompass other viral replication cycle steps such as entry, processing, assembly and secretion, or viral host factors. We previously applied a phenotypic high-throughput screening platform based on an infectious HCV system and discovered an aryloxazole-based anti-HCV hit. Structure-activity relationship studies revealed several compounds exhibiting EC50 values below 100 nM. Lead compounds showed inhibition of the HCV pseudoparticle entry, suggesting a different mode of action from existing HCV drugs. Hit 7a and lead 7ii both showed synergistic effects in combination with existing HCV drugs. In vivo pharmacokinetics studies of Iii showed high liver distribution and long half-life without obvious hepatotoxicity. The lead compounds are promising as preclinical candidates for the treatment of HCV infection and as molecular probes to study HCV pathogenesis.

  DOI：

  10.1021/acs.jmedchem.7b00561
• 作为产物：
  描述：

  4,4-二甲基哌啶 在 氨 、 氢气 、 formamide 作用下， 以 甲醇 、 水 为溶剂， 20.0 ℃ 、1.52 MPa 条件下， 反应 31.0h， 生成 3-(4,4-dimethylpiperidin-1-yl)propan-1-amine
  参考文献：
  名称：

  Development of an Aryloxazole Class of Hepatitis C Virus Inhibitors Targeting the Entry Stage of the Viral Replication Cycle

  摘要：

  Reliance on hepatitis C virus (HCV) replicon systems and protein-based screening assays has led to treatments that target HCV viral replication proteins. The model does not encompass other viral replication cycle steps such as entry, processing, assembly and secretion, or viral host factors. We previously applied a phenotypic high-throughput screening platform based on an infectious HCV system and discovered an aryloxazole-based anti-HCV hit. Structure-activity relationship studies revealed several compounds exhibiting EC50 values below 100 nM. Lead compounds showed inhibition of the HCV pseudoparticle entry, suggesting a different mode of action from existing HCV drugs. Hit 7a and lead 7ii both showed synergistic effects in combination with existing HCV drugs. In vivo pharmacokinetics studies of Iii showed high liver distribution and long half-life without obvious hepatotoxicity. The lead compounds are promising as preclinical candidates for the treatment of HCV infection and as molecular probes to study HCV pathogenesis.

  DOI：

  10.1021/acs.jmedchem.7b00561

文献信息

• Thienopyridinone compounds and methods of treatment
  申请人：Dhanoa S. Dale

  公开号：US20050256153A1

  公开（公告）日：2005-11-17

  The invention relates to 5-HT receptor agonists and partial agonists. Novel thienopyridinone compounds represented by Formula I, and synthesis and uses thereof for treating diseases mediated directly or indirectly by 5-HT receptors, are disclosed. Such conditions include Alzheimer's disease, cognition disorders, irritable bowel syndrome, nausea, emesis, vomiting, prokinesia, gastroesophageal reflux disease, nonulcer dyspepsia, depression, anxiety, urinary incontinence, migraine, arrhythmia, atrial fibrillation, ischemic stroke, gastritis, gastric emptying disorders, feeding disorders, gastrointestinal disorders, constipation, erectile dysfunction, and respiratory depression. Methods of preparation and novel intermediates and pharmaceutical salts thereof are also included.

  该发明涉及5-HT受体激动剂和部分激动剂。公开了由式I表示的新型噻吩吡啶酮化合物，以及其合成和用于治疗由5-HT受体直接或间接介导的疾病。这些疾病包括阿尔茨海默病、认知障碍、肠易激综合征、恶心、呕吐、促动力、胃食管反流病、非溃疡性消化不良、抑郁症、焦虑症、尿失禁、偏头痛、心律失常、心房颤动、缺血性中风、胃炎、胃排空障碍、进食障碍、消化道疾病、便秘、勃起功能障碍和呼吸抑制。还包括其制备方法、新颖中间体和药用盐。
• Synthesis of thienopyridinone compounds and related intermediates
  申请人：Dhanoa S. Dale

  公开号：US20060084805A1

  公开（公告）日：2006-04-20

  The invention relates to 5-HT receptor agonists and partial agonists. Novel thienopyridinone compounds represented by Formula I, and synthesis and uses thereof for treating diseases mediated directly or indirectly by 5-HT receptors, are disclosed. Such conditions include Alzheimer's disease, cognition disorders, irritable bowel syndrome, nausea, emesis, vomiting, prokinesia, gastroesophageal reflux disease, nonulcer dyspepsia, depression, anxiety, urinary incontinence, migraine, arrhythmia, atrial fibrillation, ischemic stroke, gastritis, gastric emptying disorders, feeding disorders, gastrointestinal disorders, constipation, erectile dysfunction, and respiratory depression. Methods of preparation and novel intermediates and pharmaceutical salts thereof are also included.

  本发明涉及5-HT受体激动剂和部分激动剂。公开了由式I表示的新型噻唑吡啶酮化合物及其合成和用途，用于治疗直接或间接通过5-HT受体介导的疾病。这些疾病包括阿尔茨海默病、认知障碍、肠易激综合征、恶心、呕吐、胃肠动力障碍、胃食管反流病、非溃疡性消化不良、抑郁症、焦虑症、尿失禁、偏头痛、心律失常、房颤、缺血性中风、胃炎、胃排空障碍、进食障碍、胃肠道疾病、便秘、勃起功能障碍和呼吸抑制。还包括制备方法、新型中间体和药物盐。
• Thienopyridinone Compounds and Methods of Treatment
  申请人：Dhanoa Dale S.

  公开号：US20090163537A1

  公开（公告）日：2009-06-25

  The invention relates to 5-HT receptor agonists and partial agonists. Novel thienopyridinone compounds represented by Formula I, and synthesis and uses thereof for treating diseases mediated directly or indirectly by 5-HT receptors, are disclosed. Such conditions include Alzheimer's disease, cognition disorders, irritable bowel syndrome, nausea, emesis, vomiting, prokinesia, gastroesophageal reflux disease, nonulcer dyspepsia, depression, anxiety, urinary incontinence, migraine, arrhythmia, atrial fibrillation, ischemic stroke, gastritis, gastric emptying disorders, feeding disorders, gastrointestinal disorders, constipation, erectile dysfunction, and respiratory depression. Methods of preparation and novel intermediates and pharmaceutical salts thereof are also included.

  本发明涉及5-HT受体激动剂和部分激动剂。公开了由式I表示的新型噻唑吡啶酮化合物及其合成和用于治疗直接或间接由5-HT受体介导的疾病的用途。这些疾病包括阿尔茨海默病、认知障碍、肠易激综合征、恶心、呕吐、胃肠动力障碍、胃食管反流病、非溃疡性消化不良、抑郁症、焦虑症、尿失禁、偏头痛、心律失常、房颤、缺血性中风、胃炎、胃排空障碍、进食障碍、胃肠道疾病、便秘、勃起功能障碍和呼吸抑制。还包括制备方法、新型中间体和药物盐。
• US7488736B2
  申请人：——

  公开号：US7488736B2

  公开（公告）日：2009-02-10
• US7576211B2
  申请人：——

  公开号：US7576211B2

  公开（公告）日：2009-08-18